Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Queensland 4029, Australia.
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis IN, USA.
J Hepatol. 2022 Feb;76(2):275-282. doi: 10.1016/j.jhep.2021.10.005. Epub 2021 Oct 14.
BACKGROUND & AIMS: Only a minority of excess alcohol drinkers develop cirrhosis. We developed and evaluated risk stratification scores to identify those at highest risk.
Three cohorts (GenomALC-1: n = 1,690, GenomALC-2: n = 3,037, UK Biobank: relevant n = 6,898) with a history of heavy alcohol consumption (≥80 g/day (men), ≥50 g/day (women), for ≥10 years) were included. Cases were participants with alcohol-related cirrhosis. Controls had a history of similar alcohol consumption but no evidence of liver disease. Risk scores were computed from up to 8 genetic loci identified previously as associated with alcohol-related cirrhosis and 3 clinical risk factors. Score performance for the stratification of alcohol-related cirrhosis risk was assessed and compared across the alcohol-related liver disease spectrum, including hepatocellular carcinoma (HCC).
A combination of 3 single nucleotide polymorphisms (SNPs) (PNPLA3:rs738409, SUGP1-TM6SF2:rs10401969, HSD17B13:rs6834314) and diabetes status best discriminated cirrhosis risk. The odds ratios (ORs) and (95% CIs) between the lowest (Q1) and highest (Q5) score quintiles of the 3-SNP score, based on independent allelic effect size estimates, were 5.99 (4.18-8.60) (GenomALC-1), 2.81 (2.03-3.89) (GenomALC-2), and 3.10 (2.32-4.14) (UK Biobank). Patients with diabetes and high risk scores had ORs of 14.7 (7.69-28.1) (GenomALC-1) and 17.1 (11.3-25.7) (UK Biobank) compared to those without diabetes and with low risk scores. Patients with cirrhosis and HCC had significantly higher mean risk scores than patients with cirrhosis alone (0.76 ± 0.06 vs. 0.61 ± 0.02, p = 0.007). Score performance was not significantly enhanced by information on additional genetic risk variants, body mass index or coffee consumption.
A risk score based on 3 genetic risk variants and diabetes status enables the stratification of heavy drinkers based on their risk of cirrhosis, allowing for the provision of earlier preventative interventions.
Excessive chronic drinking leads to cirrhosis in some people, but so far there is no way to identify those at high risk of developing this debilitating disease. We developed a genetic risk score that can identify patients at high risk. The risk of cirrhosis is increased >10-fold with just two risk factors - diabetes and a high genetic risk score. Risk assessment using this test could enable the early and personalised management of this disease in high-risk patients.
只有少数过量饮酒者会发展为肝硬化。我们开发并评估了风险分层评分,以确定风险最高的人群。
本研究纳入了三个队列(GenomALC-1:n=1690,GenomALC-2:n=3037,英国生物库:相关 n=6898),这些队列均有大量饮酒史(男性≥80 g/天,女性≥50 g/天,持续≥10 年)。病例组为有酒精相关肝硬化的参与者。对照组有类似的饮酒史,但没有肝脏疾病的证据。风险评分是根据先前确定的与酒精性肝硬化相关的 8 个遗传位点和 3 个临床危险因素计算得出的。评估了风险评分在酒精性肝病谱中的分层作用,包括肝细胞癌(HCC)。
3 个单核苷酸多态性(SNP)(PNPLA3:rs738409、SUGP1-TM6SF2:rs10401969、HSD17B13:rs6834314)和糖尿病状态的组合可最佳区分肝硬化风险。基于独立等位基因效应大小估计,最低(Q1)和最高(Q5)评分五分位数的 3-SNP 评分的比值比(OR)和(95%置信区间)分别为 5.99(4.18-8.60)(GenomALC-1)、2.81(2.03-3.89)(GenomALC-2)和 3.10(2.32-4.14)(英国生物库)。患有糖尿病和高风险评分的患者的 OR 分别为 14.7(7.69-28.1)(GenomALC-1)和 17.1(11.3-25.7)(英国生物库),而没有糖尿病和低风险评分的患者的 OR 分别为 14.7(7.69-28.1)和 17.1(11.3-25.7)(英国生物库)。患有肝硬化和 HCC 的患者的平均风险评分明显高于仅患有肝硬化的患者(0.76±0.06 vs. 0.61±0.02,p=0.007)。额外的遗传风险变异、体重指数或咖啡摄入量的信息并不能显著提高评分性能。
基于 3 个遗传风险变异和糖尿病状态的风险评分可根据肝硬化风险对大量饮酒者进行分层,从而为提供早期预防干预提供了可能。
非专业人士请不要尝试自行翻译,以免造成误解。